FIELD: biochemistry.
SUBSTANCE: invention relates to a binding agent that binds to the T-cell specific antigen CD3 and claudin 6 (CLDN6). Also disclosed is a nucleic acid or a mixture of nucleic acids encoding the said agent; a host cell containing the said nucleic acid; a vector or composition of vectors containing the said nucleic acid; a host cell containing the said nucleic acid; and a pharmaceutical composition containing the said agent. The use of the specified binding agent as a drug, and a method for the treatment or prevention of cancer, using the specified agent are disclosed.
EFFECT: invention makes it possible to effectively treat diseases associated claudin 6 expression.
34 cl, 14 ex, 10 tbl, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
